Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis (PsyHistio)

Assistance Publique - Hôpitaux de Paris

Status: Unknown

Conditions: Pulmonary Langerhans Cell Histiocytosis

Treatments: Other: Evaluation of co-morbid psychiatric disorders

Study type: Observational

Funder types: Other

Identifiers

NCT05114304

APHP210292

Details and patient eligibility

About

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients.

This study should allow:

• to assess the prevalence of psychiatric disorders co-morbid in PLCH patients
• a targeted and more effective management of patients
• a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of 18 years of age or older with PLCH diagnosed at adulthood
• Patients affiliated to the French Health Care System
• Informed patients

Exclusion criteria

• Patient unable to understand the interview (language barrier)
• Patient under guardianship or curatorship
• Patient under AME (French medical help for foreigners)

Trial design

100 participants in 1 patient group

Pulmonary Langerhans cell histiocytosis (PLCH)

Description:

Adults with pulmonary Langerhans cell histiocytosis

Treatment:

Other: Evaluation of co-morbid psychiatric disorders